Slingshot members are tracking this event:
FDA approves Cosentyx in treating patients with ankylosing spondylitis and psoriatic arthritis in the US
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|NVS||Community voting in process|
Slingshot Insights Explained
Jan 15, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Interleukin-17a, Il-17a, Ankylosing Spondylitis, Psoriatic Arthritis, Fda Approval, Phase Iii Studies, Secukinumab, Anti-tumor Necrosis Factor-alpha Therapy